TP53 and clostridium difficile infection: Thus, our model based on PCD is more effective in predicting survival than the existing biomarkers (Low CDI + TP53 mutation vs. High CDI + TP53 mutation, P < 0.001; Low CDI + wild TP53 vs. High CDI + wild TP53, P < 0.001; Low CDI + High neoantigen vs. High CDI + High neoantigen, P < 0.001; Low CDI + Low neoantigen vs. High CDI + Low neoantigen, P < 0.001; Low CDI + Low TMB vs. High CDI + Low TMB, P = 0.002; Low CDI + High TMB vs. High CDI + High TMB, P < 0.001) and shows great potential for use in selecting personalized treatment for patients with identical TP53, neoantigen and TMB status.